Methods: Patients were randomized to placebo, mirabegron 50 or 100 mg, or tolterodine extended release (ER) 4 mg orally, once-daily, for 12 weeks. For the post hoc analysis, the primary patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback